Drugs / AAT
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT03805789 | Mar 2019 → Mar 2026 | acute graft versus host disease | CSL Behring | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AAT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03805789 ↗ |
| Modality | Protein / enzyme biologic | “Biological: AAT” NCT03805789 ↗ |
| Route | Intravenous | “AAT is a lyophilized product for IV administration.” NCT03805789 ↗ |